<DOC>
	<DOCNO>NCT02725112</DOCNO>
	<brief_summary>This study Phase 1 , randomize , open label , single dose , 6 treatment , 6 period , 6 sequence study healthy adult volunteer . A total 24 ( 4 treatment sequence ) healthy male female subject , time screening , age 18 55 year , inclusive enrol . Subjects discontinue study may replace Sponsor 's discretion . Screening activity complete within approximately 28 day prior Day 1 Period 1 . Subjects randomize 1 6 treatment sequence describe Table 1 . Each treatment sequence consist 6 period subject receive single dos pregabalin ER 330 mg target release rate tablet , pregabalin ER 330 mg slow release rate tablet , pregabalin ER 330 mg fast release rate tablet , pregabalin IR 300 mg capsule , pregabalin ER 82.5 mg target release rate tablet , pregabalin ER 330 mg aberrant fast release rate tablet formulation . All study treatment administer follow 600- 750 calorie , 30 % fat evening meal .</brief_summary>
	<brief_title>Bioavailability Study Pregabalin Extended Release Formulation With Various Release Rates Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Pregabalin</mesh_term>
	<criteria>1 . Healthy female subject and/or male subject , time screening , age 18 55 year , inclusive . Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12 lead electrocardiogram ( ECG ) clinical laboratory test . A 1:1 ratio men woman desirable , consider protocol deviation meet . 2 . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . 3 . Evidence personally sign date informed consent document . 4 . Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure . 1 . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . 2 . History febrile illness within 5 day prior first dose study investigational product . 3 . Subjects estimate CLcr &lt; 60 mL/min derive use method Crockcroft Gault.1 4 . Any condition possibly affect drug absorption . 5 . A positive urine drug screen . 6 . Use tobacco nicotine containing product excess equivalent 5 cigarette per day . 7 . History regular alcohol consumption exceed 7 drinks/week female 14 drinks/week male ( 1 drink = 5 ounce [ 150 mL ] wine 12 ounce [ 360 mL ] beer 1.5 ounce [ 45 mL ] hard liquor ) within 6 month Screening . 8 . Treatment investigational drug within 30 day 5 half life precede first dose study investigational product ( whichever longer ) . 9 . Screening supine blood pressure &gt; = 140 mm Hg ( systolic ) &gt; = 90 mm Hg ( diastolic ) , follow least 5 minute supine rest . If blood pressure &gt; = 140 mm Hg ( systolic ) &gt; = 90 mm Hg ( diastolic ) , blood pressure repeat 2 time average 3 blood pressure value use determine subject 's eligibility . 10 . Screening supine 12 lead ECG demonstrate QTc ( time ECG Q wave end T wave correspond electrical systole [ QT ] correct heart rate ) &gt; 450 msec QRS interval ( time ECG Q wave end S wave correspond ventricle depolarization ) &gt; 120 msec . If QTc exceed 450 msec , QRS exceed 120 msec , ECG repeat 2 time average 3 QTc QRS value use determine subject 's eligibility . 11 . Pregnant female subject ; breastfeed female subject ; male subject partner currently pregnant ; male subject able father child female subject childbearing potential unwilling unable use highly effective method contraception outline protocol duration study least 28 day last dose investigational product . 12 . Use prescription ( oral , transdermal , intrauterine , implanted , injected contraceptive hormone replacement therapy ) nonprescription drug dietary supplement within 7 day 5 half life ( whichever longer ) prior first dose study medication.investigational product . Herbal supplement must discontinue least 28 day prior first dose study medicationinvestigational product . As exception , acetaminophen/paracetamol may use dos great 1 g/day . Limited use non prescription medication believe affect subject safety overall result study may permit case case basis follow approval Sponsor . 13 . Blood donation ( exclude plasma donation ) approximately 1 pint ( 500 mL ) within 56 day prior dose . 14 . History sensitivity pregabalin , gabapentin , alpha2 delta ligand . 15 . History sensitivity heparin heparin induce thrombocytopenia . 16 . Unwilling unable comply Lifestyle Guidelines describe protocol . 17 . Previous participation study involve pregabalin . 18 . Subjects investigational site staff member directly involve study , family member , site staff member otherwise supervised investigator , subject Pfizer employee directly involve study . 19 . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>